pharmexec.com
Cure8 news brief
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
Medications
Mirikizumab
IL-23 inhibitor
Urgency
Abdominal Pain
Remission
Regulatory Update
Adult patients
Why This Matters
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency. It highlights both symptom relief and measures of intestinal healing from company-reported trials.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease, patients interested in biologic options or who have had prior biologic failure, pediatric patients (research in progress), clinicians prescribing IBD therapies, and researchers following IL‑23 pathway drugs.
Study Snapshot
Story typeCompany update
Evidence typeRegulatory update
Source depthFull source text
What To Know
Omvoh is an IL‑23 p19 inhibitor that was first used in ulcerative colitis and is now discussed for Crohn’s disease based on Lilly’s VIVID‑1 trial results and subsequent regulatory decisions.
The article highlights symptom outcomes (including urgency and frequency), endoscopic and histologic measures of improvement, and longer‑term maintenance data from an open‑label extension mentioned by the company.
Lilly also describes ongoing studies: pediatric trials, long‑term UC studies, a Phase 4 real‑world study in UC, and combination research with another antibody (eltrekibart) in UC. The piece is an industry interview and presents company perspectives on development priorities and trial findings rather than independent clinical analysis.
Implications for patients These developments may expand treatment options for people with moderately to severely active Crohn’s disease, particularly for those struggling with disruptive symptoms, but changes in care depend on regulatory availability, clinician judgment, and access decisions.
Keep In Mind
This is an interview with a Lilly executive and summarizes company‑reported trial outcomes and regulatory milestones (FDA approval and CHMP positive opinion). The article reflects the company perspective; readers should consult independent trial publications, prescribing information, and regulators for full data and guidance. No new clinical recommendations are provided here.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationpharmexec.com
Indexed viaBing News
Source typeCompany update
PublishedJan 29, 2025, 3:00 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
Eli Lilly's Omvoh granted FDA approval to treat Crohn's disease in adults - PMLiVE
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...